My Blue Dots

BILLERICA, Mass.–(BUSINESS WIRE)—- $BRKR #BRKR–Bruker Corporation (Nasdaq: BRKR) today announced the launch of the LUMOS™ II ILIM, a quantum cascade laser (QCL) based infrared imaging microscope. The new LUMOS II ILIM redefines performance standards, enabling pharma and life science researchers to capture ultrafast IR images of expansive areas with enhanced spatial resolution. The LUMOS II ILIM features a patented coherence reduction method for infrared laser imaging essentially free from artifacts in both

TUTTLINGEN, Germany–(BUSINESS WIRE)–The family-owned MedTech company KARL STORZ is pleased to announce the acquisition of the medical business of T1V, a US-based visual collaboration software company. KARL STORZ has had a longstanding partnership with T1V to build its existing CollaboratOR portfolio. This acquisition marks a significant step for KARL STORZ in shaping integrated hardware and software solutions for digital surgery in global operating rooms, complementing its state-of-the-art en

DUBLIN–(BUSINESS WIRE)–ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today released the findings of a survey of over 120 biotech and pharma professionals developing treatments for neurodegenerative disorders. The findings indicate that, despite recent successes in developing disease modifying treatments for Alzheimer’s, persistent challenges that remain in neurodegenerative clinical trials can be mitigated by underutilised trial me

BOSTON–(BUSINESS WIRE)–PureTech to present at 43rd annual J.P. Morgan Healthcare Conference.

CAMBRIDGE, Mass.–(BUSINESS WIRE)–MOMA Therapeutics, a clinical-stage biopharmaceutical company discovering and developing a new generation of precision therapeutics, today announced the in-licensing of a next-generation selective PARP1 (poly ADP-ribose polymerase) inhibitor, now known as MOMA-989. The company also provided an update on the clinical progress of Polθ inhibitor MOMA-313 and outlined the clinical path for Werner inhibitor MOMA-341. “The addition of this selective PARP1 inhibitor

WALTHAM, Mass.–(BUSINESS WIRE)–MDaudit, a premier provider of billing, coding compliance and revenue integrity software for health systems, hospitals, and provider groups, announced a strategic growth investment from Bregal Sagemount (“Sagemount”), a leading growth-focused private equity firm, and Primus Capital (“Primus”), the company’s existing investor. Terms of the transaction were not disclosed. MDaudit, headquartered in Waltham, MA, specializes in delivering high-quality, customer-centr

WALTHAM, Mass.–(BUSINESS WIRE)–Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announces the company’s key priorities and catalysts for 2025. “After a great year of execution across the portfolio, we enter 2025 poised to deliver on a number of important catalysts,” said Steve Mahoney, Viridian’s President and CEO. “We believe that the positive and better-than-expect

WATERTOWN, Mass.–(BUSINESS WIRE)–Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2024 at 8:15 a.m. PT in San Francisco, CA. A live webcast of the event will be accessible by visiting the “Events and Present

RALEIGH, N.C. & OKLAHOMA CITY–(BUSINESS WIRE)–Lumata Health, a technology-driven healthcare innovator empowering ophthalmology practices to enhance continuous care for those at risk of blindness from chronic eye diseases, today formally announced its Clinical Advisory Board (CAB). The esteemed group of five leading ophthalmologists will provide strategic guidance to further Lumata’s mission of reducing preventable blindness through its turnkey, patient-centered continuous care platform. The C

SYRACUSE, N.Y.–(BUSINESS WIRE)– #ClinicalTrials–Central New York Biotech Accelerator (CNYBAC). -– Zetagen Therapeutics, Inc., a private, clinical stage, biopharmaceutical company focused on developing proprietary carriers delivering tumoricidal therapies for metastatic and primary breast cancer, which may minimize patient side effects with the potential to increase survival rates, announced today in 2024 they nearly doubled their worldwide IP portfolio to 64 patents, spanning across 36 countries including the